Dasatinib
Leukemia, Myeloid, Accelerated-Phase
Explore 12 assets in Leukemia, Myeloid, Accelerated-Phase →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03414450CT.gov Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies | — | Withdrawn | — | — | — |
NCT00316953CT.gov Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | — | Completed | — | — | — |
NCT00123487CT.gov Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Leukemia, Myeloid, Accelerated-Phase
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dasatinib (this asset) | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | P3 | B · 62 |
| Fludarabine | University of Illinois at Chicago | P2 | BBB |
| Cyclophosphamide | University of Illinois at Chicago | P2 | BBB |
| Cyclosporin A | University of Michigan Rogel Cancer Center | P2 | BBB |
| Tacrolimus | University of Michigan Rogel Cancer Center | P2 | BB |
| Nivestim | Roswell Park Cancer Institute | P2 | BB |
| Methotrexate | University of Michigan Rogel Cancer Center | P2 | BB |
| Busulfanum | University of Illinois at Chicago | P2 | BB |
| Vorinostat | University of Michigan Rogel Cancer Center | P2 | B |
+38 more in the Leukemia, Myeloid, Accelerated-Phase cohort
Other indications for Dasatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Acute Lymphoblastic Leukemia | — | P3 | BB · 70 |
| Chronic Myeloid Leukemia | — | P2/3 | BB · 68 |
| B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2) | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dasatinib in Leukemia, Myeloid, Accelerated-Phase. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dasatinib-leukemia-myeloid-accelerated-phase
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →